Acetylon with the financial support of The Leukemia and Lymphoma Society (White Plains, NY) is currently initiating a Phase 1-2 clinical trial of the oral, selective, small molecule HDAC6 inhibitor ACY-1215 in relapsed and relapsed/refractory multiple myeloma at six participating major US teaching hospitals.  For more information about the clinical trial, use the following link: http://www.clinicaltrials.gov/ct2/show/NCT01323751.